CL2023002236A1 - Métodos para tratar la amiloidosis primaria - Google Patents

Métodos para tratar la amiloidosis primaria

Info

Publication number
CL2023002236A1
CL2023002236A1 CL2023002236A CL2023002236A CL2023002236A1 CL 2023002236 A1 CL2023002236 A1 CL 2023002236A1 CL 2023002236 A CL2023002236 A CL 2023002236A CL 2023002236 A CL2023002236 A CL 2023002236A CL 2023002236 A1 CL2023002236 A1 CL 2023002236A1
Authority
CL
Chile
Prior art keywords
methods
primary amyloidosis
treat primary
amyloidosis
treat
Prior art date
Application number
CL2023002236A
Other languages
English (en)
Spanish (es)
Inventor
Kinney Gene
Zago Wagner
Tripuraneni RADHIKA
KARP Carol
Original Assignee
Prothena Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prothena Biosciences Ltd filed Critical Prothena Biosciences Ltd
Publication of CL2023002236A1 publication Critical patent/CL2023002236A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Chemical Treatment Of Metals (AREA)
CL2023002236A 2021-01-29 2023-07-28 Métodos para tratar la amiloidosis primaria CL2023002236A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163143728P 2021-01-29 2021-01-29

Publications (1)

Publication Number Publication Date
CL2023002236A1 true CL2023002236A1 (es) 2024-02-09

Family

ID=80222587

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023002236A CL2023002236A1 (es) 2021-01-29 2023-07-28 Métodos para tratar la amiloidosis primaria

Country Status (13)

Country Link
US (1) US20250084153A1 (https=)
EP (1) EP4284829A1 (https=)
JP (1) JP2024505923A (https=)
KR (1) KR20230136643A (https=)
CN (1) CN117098775A (https=)
AU (1) AU2022213010A1 (https=)
CA (1) CA3206326A1 (https=)
CL (1) CL2023002236A1 (https=)
IL (1) IL304755A (https=)
JO (1) JOP20230172A1 (https=)
MX (1) MX2023008835A (https=)
TW (1) TW202332465A (https=)
WO (1) WO2022162625A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021552135A1 (en) 2019-03-05 2022-08-31 Prothena Biosciences Ltd Methods of treating al amyloidosis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018005967A1 (en) * 2016-06-30 2018-01-04 Prothena Therapeutics Limited Compositions for treating amyloidosis
US11382974B2 (en) * 2017-08-01 2022-07-12 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases
PH12021552135A1 (en) * 2019-03-05 2022-08-31 Prothena Biosciences Ltd Methods of treating al amyloidosis

Also Published As

Publication number Publication date
US20250084153A1 (en) 2025-03-13
EP4284829A1 (en) 2023-12-06
JOP20230172A1 (ar) 2023-07-27
KR20230136643A (ko) 2023-09-26
IL304755A (en) 2023-09-01
CN117098775A (zh) 2023-11-21
AU2022213010A1 (en) 2023-08-17
WO2022162625A1 (en) 2022-08-04
AU2022213010A9 (en) 2024-09-26
TW202332465A (zh) 2023-08-16
CA3206326A1 (en) 2022-08-04
JP2024505923A (ja) 2024-02-08
MX2023008835A (es) 2023-09-08

Similar Documents

Publication Publication Date Title
CL2021002318A1 (es) Métodos de tratamiento de amiloidosis al
ECSP21093541A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados con braf
CO2022010330A2 (es) Dosificación de gamma-hidroxibutirato (ghb)
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
CR20200334A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX2018012390A (es) Composiciones de disulfuro de selenio para usarse en el tratamiento de la disfuncion de las glandulas de meibomio.
MX378872B (es) Inhibidores pcsk9 para usarse en el tratamiento de hipercolesterolemia.
CO2022000481A2 (es) Inhibidores de enzimas
BR112015026247A2 (pt) métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia
JOP20230157A1 (ar) طرق مُعالجة فيروس كورونا
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CL2022000967A1 (es) Composiciones y métodos para el tratamiento de enfermedades hepáticas
EA202190261A1 (ru) Топические маслянистые композиции
CO2022001354A2 (es) Métodos para tratar o prevenir la atrofia muscular espinal
CL2023001637A1 (es) Inhibidores de la vía jak1 para el tratamiento del vitíligo.
CO2022000266A2 (es) Inhibidores de enzimas
CL2021001554A1 (es) Métodos para el tratamiento de discinesia en parálisis cerebral.
CL2022002684A1 (es) Composiciones de anticuerpo anti-cd6 y métodos para tratar y reducir efectos negativos de un coronavirus
CL2023002236A1 (es) Métodos para tratar la amiloidosis primaria
CL2024002103A1 (es) Métodos para tratar amiloidosis al
CL2022002589A1 (es) Tratamiento de trastornos respiratorios
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.